Literature DB >> 13396092

Further studies on the plasma lymphocytosis stimulating factor in chronic lymphatic leukaemia and some other disease states.

D METCALF.   

Abstract

Entities:  

Keywords:  BLOOD; BONE MARROW/diseases; LEUKEMIA, LYMPHATIC/blood in; LYMPHOCYTOSIS; LYMPHOSARCOMA/blood in

Mesh:

Year:  1956        PMID: 13396092      PMCID: PMC2073832          DOI: 10.1038/bjc.1956.50

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  The natural history of untreated acute leukemia.

Authors:  H TIVEY
Journal:  Ann N Y Acad Sci       Date:  1954-12-06       Impact factor: 5.691

2.  Primary and secondary leucocyte changes following the intramuscular injection of epinephrine hydrochloride.

Authors:  A J SAMUELS
Journal:  J Clin Invest       Date:  1951-09       Impact factor: 14.808

3.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

4.  The present position regarding leukaemia.

Authors:  L WHITBY
Journal:  West J Surg Obstet Gynecol       Date:  1951-04

5.  Presence of myelokentric and lymphokentric acid in sera of patients with lymphomatoid diseases.

Authors:  C G FOSTER; F R MILLER
Journal:  Proc Soc Exp Biol Med       Date:  1950-12

6.  The effect of administration of epinephrine on the leukocyte counts of normal subjects.

Authors:  C WHITE; T H LING; A M KLEIN
Journal:  Blood       Date:  1950-08       Impact factor: 22.113

  6 in total
  2 in total

1.  Heterotransplantation of human tumours and tissues.

Authors:  F C CHESTERMAN
Journal:  Ann R Coll Surg Engl       Date:  1959-07       Impact factor: 1.891

2.  Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes.

Authors:  J F Miller; G F Mitchell
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.